Optocred Pharmaceuticals has introduced a variety of eye-care products that are both high-quality and affordable as well as effective remedy for all eye diseases, in the midst of Covid-19 pandemic. Diminfect and Diminfect D are the first Moxifloxacin and Moxifloxacin-Dexamethasone eye drops in India marketed in 10ml vials each, and are hailed as a super conqueror and a amazing combo for the treatment of eye illnesses.
According to Optocred, Credohyl is a revolutionary product in the ophthalmic sector. It is the first sodium hyaluronate ophthalmic solution containing 0.18 percent sodium hyaluronate coupled with Coenzyme Q10 and Tocopherol (Vitamin E) for additional lubrication and unique antioxidant activity. Credolube eye drops is the first ultimate coolant in India with improved D-panthenol action, while Allercred is the first ophthalmic anti-allergic kit in India.
According to data from the American Academy of Optometry, people who spend over two hours each day on a computer are at risk of getting computer vision syndrome. When you are reading or staring at a computer or smartphone screen for a long time, you blink less frequently. The normal blink rate, on the other hand, is 12-14 times per minute. Around 60 million individuals around the world suffer from computer vision syndrome.
Optocred Pharmaceuticals, incorporated in 2022, is managed by highly qualified and experienced quality assurance, production, and research and development teams. The company has achieved numerous firsts in the Indian ophthalmic industry, with the primary goal of assisting patients through continued innovation and research. Further, it has partnered with the top WHO-GMP/FSSAI/ISO certified manufacturing plants in India, and over 60% of its ophthalmological goods are BAK-free.
According to the company spokesperson, the pandemic-induced digitalization has led to rise in eye strain. He said, “We are committed to delivering high-quality products of an international standard that meet and exceed customer expectations. With Covid, everything went online, and the growing use of electronic gadgets resulted in a rise in eye strain. We recognised the significant risk this poses to human eyes and decided to work in the ophthalmic sector to raise patient awareness and, if necessary, offer them high-quality treatments.”
